Protective role of pravastatin in the pathogenesis of the metabolic syndrome

Medical Hypotheses

Volumn 66, Issue 3, 2006, Pages 609-611

  Yamagishi, S ^a   Matsui, T ^a   Sato, T ^b   Takeuchi, M ^b  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HOKURIKU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK REDUCTION;

CLINICAL TRIALS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MODELS, BIOLOGICAL; MODELS, THEORETICAL; OBESITY; PRAVASTATIN;

EID: 30344439499     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2005.08.004     Document Type: Article

References (16)

1. A.J. Scheen Management of the metabolic syndrome Minerva Endocrinol 29 2004 31 45
2. M. Khamaisi, I.D. Wexler, and J. Skrha Cardiovascular disease in type 2 diabetics: epidemiology, risk factors and therapeutic modalities Israel Med Assoc J 5 2003 801 806
3. J.R. Sowers Insulin resistance and hypertension Am J Physiol Heart Circ Physiol 286 2004 H1597 H1602
4. S. Yamagishi, and M. Takeuchi Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property Med Hypotheses 64 2005 476 478
5. K.E. Watson, A.L. Peters Harmel, and G. Matson Atherosclerosis in type 2 diabetes mellitus: the role of insulin resistance Cardiovasc Pharmacol Ther 8 2003 253 260
6. J.C. Mason Statins and their role in vascular protection Clin Sci 105 2003 251 266
7. B.K. Singh, and J.L. Mehta Management of dyslipidemia in the primary prevention of coronary heart disease Curr Opin Cardiol 17 2002 503 511
8. J. Auer, R. Berent, T. Weber, and B. Eber Clinical significance of pleiotropic effects of statins: lipid reduction and beyond Curr Med Chem 9 2002 1831 1850
9. Heart Protection Study Collaboration Group MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial Lancet 360 2002 7 22
10. R. Collins, J. Armitage, S. Parish, P. Sleigh, R. Peto Heart Protection Study Collaboration Group MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial Lancet 361 2003 2005 2016
11. H.M. Colhoun, and D.J. Betteridge Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study CARDS: multicentre randomized placebo-controlled trial Lancet 364 2004 685 696
12. S. Stender, H. Schuster, P. Barter, C. Watkins, D. Kallend MERCURY 1 Study Group Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial Diabetes Obes Metab 7 2005 430 438
13. P.C. Deedwania, D.B. Hunninghake, and H.E. Bays Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome Am J Cardiol 95 2005 360 366
14. J. Scepherd, S.M. Cobbe, I. Ford West of Scotlan Coronary Prevention Study Group Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia N Engl J Med 333 1995 1301 1307
15. F. Guclu, B. Ozmen, Z. Hekimsoy, and C. Kirmaz Effects of a statin group drug, pravastatin, on the insulin resistance in patients with metabolic syndrome Biomed Pharmacother 58 2004 614 618
16. K. Kobayashi Adipokines: therapeutic targets for metabolic syndrome Curr Drugs Targets 6 2005 525 529